Vaccine Global Congress 2017 Europe

Vaccine Global Congress 2017 Europe

Press Release ( - LONDON - Jan 18, 2017 - Progress in virology, genetics, synthetic biology, and biotechnology has provided a new set of tools to approach current-day vaccinology, while increased understanding of human immunity and microbes has catalyzed unprecedented advances that can be adopted to improve public health. Despite continuing challenges, the collective effort of governments and nonprofit organizations to expand the utilization of effective vaccines throughout the world has grown.

In the upcoming 2017 Vaccine Congress, dynamic approach to key trends, methodologies and insights on new vaccine platforms for cancer and emerging diseases, manufacturing trends, and regulatory compliance is anticipated. Gain latest insights on:

• Latest developments on new adjuvant technologies and novel immunotherapies in the treatment of cancer and emerging viral diseases
• Comprehensive insights on new technological developments in vaccine production
• Regulatory approach and economic consideration on vaccine trials

Who you will meet

Network with cancer geneticists, cancer biologists, experts in cancer antigen presentation, tumor immunologists, vaccinologists, senior VPs, Heads, Directors and Managers of leading biopharmaceutical and biotech companies whose responsibilities include manufacturing, research and development, regulatory and marketing, government and non-government vaccine leads.

Source : Paradigm Global Events
Business Info :
Paradigm Global Events

You may also like this  



Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Or form here

Already have an account ? Login

Reset Password

Already have an account ? Login


If you have any concerns regarding this press release, please contact the Author / Media Contact / Business of this press release. ePRNews is not resposible for the accuracy of the news posted and do not endorse, support any product/ services/ business mentioned and hereby disclaims any content contained in this press release.